 LEXINGTON, Mass., Dec. 22, 2020 GLOBE NEWSWIRE -- Translate Bio Nasdaq: TBIO, a clinical-stage messenger RNA mRNA therapeutics company developing a new class of potentially transformative medicines to treat or prevent debilitating or life-threatening diseases, announced today that John Schroer, the Companys Chief Financial Officer CFO, is departing the Company for personal reasons. Mr. Schroers departure will be effective by year-end 2020. Robert Prentiss, Translate Bios Vice President and Corporate Controller since 2017, will serve as Principal Accounting Officer and report directly to the Companys Chief Executive Officer, Ronald Renaud, on an interim basis while a formal search process to appoint a new CFO is conducted. 